Evidence map›Paper›PMID 39232704›Full record

ArticleBMC cancer2024

CD25

Asami Suto, Takeo Minaguchi, Nan Qi, Kaoru Fujieda, Hiroya Itagaki, Yuri Tenjimbayashi, Ayumi Shikama, Nobutaka Tasaka, Azusa Akiyama, Sari Nakao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Asami SutoDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Takeo MinaguchiDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan. minaguchit@md.tsukuba.ac.jp.
Nan QiDoctoral Program in Obstetrics and Gynecology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Kaoru FujiedaDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Hiroya ItagakiDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Yuri TenjimbayashiDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Ayumi ShikamaDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Nobutaka TasakaDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Azusa AkiyamaDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Sari NakaoDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Chigusa Nakahashi-OdaDepartment of Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yusuke KobayashiDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.
Akira ShibuyaDepartment of Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Toyomi SatohDepartment of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, 305-8575, Ibaraki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegulatory T (Treg) cells reportedly play crucial roles in tumor angiogenesis as well as antitumor immunity. In order to explore their therapeutic potential, we investigated the precise prognostic impact of Treg markers in endometrial carcinoma.

methodsWe performed multiplexed immunofluorescence and quantitative image analyses of CD25, FOXP3, CTLA4, and CD45RA in tumor specimens from 176 consecutive patients treated at our institution for primary endometrial carcinomas. Bioinformatics analyses were further conducted to corroborate the findings.

resultsHigh CD25

conclusionThe current observations suggest that the balance between CD25

Indexed as

Biomarkers, TumorEndometrial NeoplasmsForkhead Transcription FactorsInterleukin-2 Receptor alpha SubunitLeukocyte Common AntigensT-Lymphocytes, RegulatoryAdultAgedAged, 80 and overCTLA-4 AntigenFemaleHumansKaplan-Meier EstimateLymphocytes, Tumor-InfiltratingMiddle AgedPrognosisBiomarkers, TumorCTLA-4 AntigenCTLA4 protein, humanForkhead Transcription FactorsFOXP3 protein, humanIL2RA protein, humanInterleukin-2 Receptor alpha SubunitLeukocyte Common AntigensCD25CD45RAEndometrial carcinomaFOXP3SurvivalTreg cell

Identifiers

PMID39232704
PMCPMC11373268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.